Archived Insight | January 13, 2021

HHS Extends the National Public Health Emergency into April

The federal government has extended the COVID-19 public health emergency for an additional 90 days, until April 21, 2021.

This is the fourth extension of the emergency, which the secretary of the Department of Health and Human Services initially declared on January 31, 2020 (retroactive to January 27, 2020). The secretary could terminate the public health emergency earlier than April 21, 2021 or extend it again.

National Public Health Emergency extended into April

This public emergency declaration is important to health plan sponsors because it determines the period of time during which group health plans and insurers must pay for COVID-19 tests and related services without charging cost sharing. In addition, non-grandfathered plans must cover vaccines in network as a preventive benefit, but during the public emergency must also cover it on an out-of-network basis.

Have questions about how the emergency declarations affect your health plan?

We have answers.

Get in Touch

See more insights

Asian Female Pharmacist Uses Computer To Check Inventory For A Drug

Designing and Negotiating Affordable Pharmacy Benefits

Learn how health plan sponsors can improve pharmacy benefit value through PBM contracting, formulary management and clinical oversight.

Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Corporate, Pharmaceutical, Healthcare Cost Management

Read Full Insight

Focused Business Woman Working On Laptop Computer Reading

Many Retirement Plans Must Be Amended by December 31, 2026

Learn which retirement plans must be amended by December 31, 2026 and how SECURE Act discretionary and required amendments differ.

Retirement, Compliance, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Corporate

Read Full Insight

Man Self Injecting GLP 1 Weight Loss Medication Pen At Home

GLP-1s Have Disrupted the Market for Other Diabetes Drugs

Segal’s SHAPE data shows how rising GLP-1 use coincided with declines in insulin, Metformin and DPP-4 inhibitor use.

Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Corporate, Pharmaceutical

Read Full Insight

This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.